Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
4/2019 ceased to operate
BARcure
BARcure Overview
BARcure provides a therapeutic platform applicable to various B-cell neoplasms, primarily non-Hodgkins lymphoma (NHL). The company is currently focusing on the development of two BAR-based products for the treatment of DLBCL and MCL.
BARcure specifically targets malignant B cells with novel immunotherapies designed to kill tumor cells while sparing normal B cells. The company leverages the robust research work done by Prof. Michael Pfreundschuh from Saarland University in Germany.